Rescriptor® (delavirdine mesylate) – Product discontinuation

- On May 11, 2017, the FDA announced the discontinuation of ViiV Healthcare's Rescriptor (delavirdine mesylate) 100 mg and 200 mg tablets due to business reasons.
    - The discontinuation is not due to product quality, safety, or efficacy concerns.
    - The anticipated final date of availability for the 100 mg tablets is October 2018.
    - The anticipated final date of availability for the 200 mg tablets is February 2020.
- Rescriptor is indicated for the treatment of human immunodeficiency virus type 1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted.
    - Resistant virus emerges rapidly when Rescriptor is administered as monotherapy. Therefore, Rescriptor should always be administered in combination with other antiretroviral agents.
- Other non-nucleoside reverse transcriptase inhibitors that share similar indications as Rescriptor include Edurant® (rilpivirine), Intelence® (etravirine), nevirapine, nevirapine extended-release, and Sustiva® (efavirenz).

Refer to the individual drug labels for specific indication and dosing information.